YC W21
Valink Therapeutics
Discovering bispecific antibody drug-conjugates (BsADC) against cancer
About
Valink Therapeutics develops next generation antibody-based therapeutics. We identify novel mechanism of action from known targets by incorporating multiple antibody modifications at once, rapidly and scalable generating complex drug candidates (bi-/multispecificity, multivalency and drug-conjugation in a single discovery process). Our research focus is on solid tumours poorly addressed by immunotherapy.
Founders
- Arne Scheu
- Irsyad Khairil
Family Office Investors
Altss tracks family office allocations to YC-backed companies. Request access to see which family offices have invested in Valink Therapeutics.
See family office activityIndustry & Focus
HealthcareTherapeuticsBiotechDrug discovery